Jazz Pharmaceuticals Third Quarter 2022 Earnings: EPS Misses Expectations

Jazz Pharmaceuticals (NASDAQ:JAZZ) Third Quarter 2022 Results

Key Financial Results

• Revenue: US$940.7m (up 12% from 3Q 2021).
• Net loss: US$19.6m (loss narrowed by 63% from 3Q 2021).
• US$0.31 loss per share (improved from US$0.86 loss in 3Q 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Jazz Pharmaceuticals EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.

Looking ahead, revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 3.4% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Jazz Pharmaceuticals (1 is significant!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.